CSL Ltd (CSL) - Total Liabilities

Latest as of June 2025: AU$18.06 Billion AUD

Based on the latest financial reports, CSL Ltd (CSL) has total liabilities worth AU$18.06 Billion AUD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

CSL Ltd - Total Liabilities Trend (1993–2025)

This chart illustrates how CSL Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

CSL Ltd Competitors by Total Liabilities

The table below lists competitors of CSL Ltd ranked by their total liabilities.

Company Country Total Liabilities
Xcel Energy Inc
NASDAQ:XEL
USA $67.27 Billion
Orange S.A.
PA:ORA
France €74.26 Billion
Svenska Handelsbanken ser. B
LSE:0R7S
UK Skr3.28 Trillion
Sea Limited
SA:S2EA34
Brazil R$16.56 Billion
Comfort Systems USA Inc
NYSE:FIX
USA $3.54 Billion
Bank Central Asia Tbk
JK:BBCA
Indonesia Rp1242.32 Trillion
CITIC Securities Co Ltd
SHG:600030
China CN¥1.76 Trillion
Targa Resources Inc
NYSE:TRGP
USA $21.34 Billion

Liability Composition Analysis (1993–2025)

This chart breaks down CSL Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.46 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.93 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CSL Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CSL Ltd (1993–2025)

The table below shows the annual total liabilities of CSL Ltd from 1993 to 2025.

Year Total Liabilities Change
2025-06-30 AU$18.00 Billion -3.35%
2024-06-30 AU$18.62 Billion -32.66%
2023-06-30 AU$27.65 Billion +38.12%
2022-06-30 AU$20.02 Billion +105.59%
2021-06-30 AU$9.74 Billion +8.97%
2020-06-30 AU$8.94 Billion +27.65%
2019-06-30 AU$7.00 Billion +5.57%
2018-06-30 AU$6.63 Billion +11.30%
2017-06-30 AU$5.96 Billion +19.89%
2016-06-30 AU$4.97 Billion +78.87%
2015-06-30 AU$2.78 Billion -10.81%
2014-06-30 AU$3.12 Billion +4.95%
2013-06-30 AU$2.97 Billion +19.91%
2012-06-30 AU$2.48 Billion +52.13%
2011-06-30 AU$1.63 Billion +51.89%
2010-06-30 AU$1.07 Billion -12.78%
2009-06-30 AU$1.23 Billion -32.03%
2008-06-30 AU$1.81 Billion +30.20%
2007-06-30 AU$1.39 Billion +15.38%
2006-06-30 AU$1.20 Billion +15.75%
2005-06-30 AU$1.04 Billion -17.48%
2004-06-30 AU$1.26 Billion +193.86%
2003-06-30 AU$428.58 Million -26.73%
2002-06-30 AU$584.95 Million +148.92%
2001-06-30 AU$235.00 Million +328.91%
2000-06-30 AU$54.79 Million -15.82%
1999-06-30 AU$65.08 Million +27.24%
1998-06-30 AU$51.15 Million -54.16%
1997-06-30 AU$111.59 Million +34.88%
1996-06-30 AU$82.73 Million +15.84%
1995-06-30 AU$71.42 Million -12.21%
1994-06-30 AU$81.35 Million +151.07%
1993-06-30 AU$32.40 Million --

About CSL Ltd

AU:CSL Australia Biotechnology
Market Cap
$47.22 Billion
AU$66.73 Billion AUD
Market Cap Rank
#494 Global
#6 in Australia
Share Price
AU$137.55
Change (1 day)
-1.36%
52-Week Range
AU$134.62 - AU$272.00
All Time High
AU$321.70
About

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more